Clinical Trial Update: The Desensitization Therapy With GB-0998 for Anti-donor Antibody-positive Recipients. [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 trial evaluating desensitization therapy with GB-0998 for anti-donor antibody-positive recipients in end-stage renal disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• GB-0998

Snippet

Sponsor: Japan Blood Products Organization | Conditions: End Stage Renal Disease | Phase 2, Phase 3 | Status: COMPLETED